



June 7, 2021

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Enclosed is a Press Release as regards receipt of U.S. FDA approval for the Company's Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, to market a generic equivalent of Truvada® Tablets, 200 mg/300 mg of Gilead Sciences, Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

FOR LUPIN LIMITED

**Rajvardhan
Vishnu Satam**

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, o=Personal,
2.5.4.20=e8a002ede68da3b7e41e01d21c2b9062761a29a5f00491
762a5ac549cb034cae, postalCode=400104, st=Maharashtra,
serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726
cbb67a2ff09c4242771b2a, cn=Rajvardhan Vishnu Satam
Date: 2021.06.07 13:09:30 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS -1 1973)**

Encl- : a/a.

Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Mumbai, Baltimore, June 07, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received approval for its Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Truvada® Tablets, 200 mg/300 mg, of Gilead Sciences, Inc. The product will be manufactured at Lupin's facility in Nagpur, India.

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is also used for for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (RLD: Truvada®) had estimated annual sales of USD 2.1 billion in the U.S. (IQVIA MAT March 2021).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal Head – Corporate Communications Email: shwetamunjal@lupin.com	Manjira Sharma General Manager – Corporate Communications Email: manjirasharma@lupin.com
--	--



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

[*Safe Harbor Statement](#)

Truvada® is a registered trademark of Gilead Sciences Inc.